ILD Treatment
Jul 13, 2026
Monoclonal Antibodies Fueling the Next Wave of Growth in the Interstitial Lung Disease Treatment
Summary ILD is a heterogeneous group of 200+ chronic lung disorders marked by inflammation and progressive scarring that cause worsening breathlessness, declining lung function, and shortened life expectancy. Monoclonal antibodies (mAbs) are reshaping ILD care by precisely targeting inflammatory and fibrotic...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
